Skip to content
10-K

Annual Report

Corbus Pharmaceuticals Holdings, Inc. CRBP

0001193125-26-098530

← back to feed
Filed
Mar 9, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 6, 2026 17.74M sh
Shares Diluted FY 2025 · Dec 31, 2025 13.32M sh
Shares Diluted FY 2025 · Dec 31, 2024 10.92M sh
Capex FY 2025 · Dec 31, 2025 $7K
Capex FY 2025 · Dec 31, 2024 $0
Operating Cash Flow FY 2025 · Dec 31, 2025 −$64.49M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$41.79M
Short Term Investments FY 2025 · Dec 31, 2025 $134.78M
Short Term Investments FY 2025 · Dec 31, 2024 $131.86M
Cash And Equivalents FY 2025 · Dec 31, 2025 $28.49M
Cash And Equivalents FY 2025 · Dec 31, 2024 $17.2M
Stockholders Equity FY 2025 · Dec 31, 2025 $147.5M
Stockholders Equity FY 2025 · Dec 31, 2024 $142.43M
Stockholders Equity restated FY 2025 · Dec 31, 2023 −$6.91M
Current Liabilities FY 2025 · Dec 31, 2025 $20.69M
Current Liabilities FY 2025 · Dec 31, 2024 $11.82M
Total Liabilities FY 2025 · Dec 31, 2025 $20.69M
Total Liabilities FY 2025 · Dec 31, 2024 $13.45M
Current Assets FY 2025 · Dec 31, 2025 $166.95M
Current Assets FY 2025 · Dec 31, 2024 $152.98M
Total Assets FY 2025 · Dec 31, 2025 $168.2M
Total Assets FY 2025 · Dec 31, 2024 $155.88M
Eps Diluted FY 2025 · Dec 31, 2025 −$5.90
Eps Diluted FY 2025 · Dec 31, 2024 −$3.68
Eps Basic FY 2025 · Dec 31, 2025 −$5.90
Eps Basic FY 2025 · Dec 31, 2024 −$3.68
Sga Expense FY 2025 · Dec 31, 2025 $15.22M
Sga Expense FY 2025 · Dec 31, 2024 $16.5M
Rd Expense FY 2025 · Dec 31, 2025 $70.1M
Rd Expense FY 2025 · Dec 31, 2024 $32.22M
Net Income FY 2025 · Dec 31, 2025 −$78.54M
Net Income FY 2025 · Dec 31, 2024 −$40.21M
Operating Income FY 2025 · Dec 31, 2025 −$85.31M
Operating Income FY 2025 · Dec 31, 2024 −$48.72M